Short answer: Yes, and this is backed by one of the more substantial bodies of clinical evidence in the omega-3 research world. A large 2023 meta-analysis pooling data from 19 randomized controlled trials and more than 4,000 patients found that omega-3 supplementation produced significant improvements across multiple measures of dry eye disease, with the benefit growing stronger at higher doses, longer treatment durations, and higher EPA content specifically. One large, well-designed trial did buck this trend, which is worth knowing about honestly, but the overall weight of evidence leans clearly positive.
What the Strongest Evidence Shows
Dry eye disease is a genuinely well-studied area for omega-3 research, with a meaningful number of trials to draw on. The 2023 meta-analysis, which reviewed a decade of published trials, found that patients given omega-3 treatment showed significantly greater improvements in dry eye symptoms, tear break-up time, Schirmer’s test scores, corneal staining, and tear osmolarity compared with those on placebo, across a combined sample of 4,246 patients with dry eye from various underlying causes. That’s a large, diverse body of evidence pointing in the same direction across several different, objectively measurable outcomes, not just self-reported symptom scores.
What makes this finding particularly credible is the dose-response pattern researchers identified within it. The same analysis found that daily omega-3 dose, duration of intake, and the percentage of EPA specifically all showed a significant positive correlation with reduced dry eye symptoms, meaning higher doses and longer use produced measurably better results, and formulations with more EPA relative to DHA performed better. A dose-dependent relationship like this is exactly the kind of pattern that makes a treatment effect look genuinely biological rather than coincidental.
Worth Knowing: One Large Trial Found No Benefit
In the interest of giving the complete picture, a large, NIH-funded trial called DREAM, published in the New England Journal of Medicine, tested a substantial 3,000-milligram daily dose in 535 patients with moderate-to-severe dry eye disease over a full year and found no significant difference in outcomes between the omega-3 group and a placebo group, both of which improved similarly over the course of the study. This was a well-designed trial, and it’s a legitimate part of the evidence record.
A few details help make sense of why this one trial diverged from the broader meta-analytic pattern. DREAM used relatively broad inclusion criteria, enrolling patients with dry eye from a wide range of underlying causes and severities, which can dilute a treatment effect if the benefit is concentrated in specific patient subgroups rather than showing up uniformly. It’s also worth noting that DREAM’s placebo was refined olive oil, and some researchers have pointed out that olive oil itself shows biological activity relevant to eye and cell membrane health in other research, raising a similar question to the placebo debates seen in other areas of omega-3 research, about whether the comparison arm was as fully inert as intended.
What This Means in Practice
Taken together, the larger and more diverse body of trial evidence, spanning nineteen studies and thousands of patients with a clear dose-response relationship, supports a real, meaningful benefit for dry eye symptoms, particularly at adequate doses and with higher EPA content. The DREAM trial is a legitimate data point suggesting the effect may not be universal across every patient population or every trial design, but it stands as something of an outlier against a broader and more consistent body of evidence rather than the final word on the question.
- The strongest evidence comes from a 2023 meta-analysis of over 4,000 patients across 19 trials, which found significant improvement across multiple objective and symptom-based measures. This is a substantial, credible body of evidence.
- Higher doses, longer treatment duration, and higher EPA content were all associated with better results. This dose-response pattern strengthens confidence that the effect is real.
- One large trial (DREAM) found no benefit, and it’s a legitimate part of the record worth knowing about. Broad patient inclusion criteria and questions about the olive oil placebo may help explain why it diverged from the broader pattern.
If dry eye is something you’re dealing with, the evidence genuinely supports omega-3 as a reasonable option worth discussing with an eye doctor, particularly given how consistently the benefit has shown up across a large, diverse body of clinical trials.
